Glioblastoma is indeed one of the most aggressive and lethal forms of brain cancer, characterized by its rapid growth and resistance to conventional therapies. The…
The RADICALS-RT (Radiotherapy – Adjuvant Versus Early Salvage) trial is a significant study that aimed to determine the optimal timing of radiotherapy after radical prostatectomy…
Tumor Mutational Burden (TMB) is a promising biomarker for predicting the efficacy of immune checkpoint inhibitors (ICIs) like pembrolizumab. The Food and Drug Administration (FDA)…
Antibody-drug conjugates (ADCs) represent a rapidly growing class of targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs.…
This information will be used to contact you